Skip to main content

Table 3 Characteristics of 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agents

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference

Year

n

Treatment regimen

Stage IV (%)

Male (%)

PS 0–1 (%)

Oettle

2005

282

Gem 1000 mg/m2 for 3 of 4 wks

92

54

88

  

283

Gem 1250 mg/m2 d1, 8 + Pemetrexed 500 mg/m2 d8 q 3 wks

90

60

85

Rocha Lima

2004

180

Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks

81

53

74

  

180

Gem 1000 mg/m2 + Irinotecan 100 mg/m2 d1+8 q 3 wks

82

57

78

Stathopoulos

2006

70

Gem 900 mg/m2 for 3 of 4 wks

86

60

86

  

60

Gem 900 mg/m2 d1, 8 + Irinotecan 300 mg/m2 d8, q 4 wks

78

65

87

O'Reilly

2004

174

Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks

78

57

52*

  

175

Gem 1000 mg/m2 d1, 8 + Exatecan 2 mg/m2 d1+8 q 3 wks

79

53

51*

  1. * KPS = 90–100%; PS = performance status;